Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

Open access
Falsey, Ann R., Sobieszczyk, Magdalena E., Hirsch, Ian, Sproule, Stephanie, Robb, Merlin L., Corey, Lawrence, Neuzil, Kathleen M., Hahn, William, Hunt, Julie, Mulligan, Mark J., McEvoy, Charlene, DeJesus, Edwin, Hassman, Michael, Little, Susan J., Pahud, Barbara A., Durbin, Anna, Pickrell, Paul, Daar, Eric S., Bush, Larry, Solis, Joel, Carr, Quito Osuna, Oyedele, Temitope, Buchbinder, Susan, Cowden, Jessica, Vargas, Sergio L., Guerreros Benavides, Alfredo, Call, Robert, Keefer, Michael C., Kirkpatrick, Beth D., Pullman, John, Tong, Tina, Brewinski Isaacs, Margaret, Benkeser, David, Janes, Holly E., Nason, Martha C., Green, Justin A., Kelly, Elizabeth J., Maaske, Jill, Mueller, Nancy, Shoemaker, Kathryn, Takas, Therese, Marshall, Richard P., Pangalos, Menelas N., Villafana, Tonya, Gonzalez-Lopez, Antonio · 2021 · New England Journal of Medicine

Abstract

BACKGROUND: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known. METHODS: In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru. RESULTS: A total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P<0.001) and estimated vaccine efficacy was 83.5% (95% CI, 54.2 to 94.1) in participants 65 years of age or older. High vaccine efficacy was consistent across a range of demographic subgroups. In the fully vaccinated analysis subgroup, no severe or critical symptomatic Covid-19 cases were observed among the 17,662 participants in the AZD1222 group; 8 cases were noted among the 8550 participants in the placebo group (<0.1%). The estimated vaccine efficacy for preventing SARS-CoV-2 infection (nucleocapsid antibody seroconversion) was 64.3% (95% CI, 56.1 to 71.0; P<0.001). SARS-CoV-2 spike protein binding and neutralizing antibodies increased after the first dose and increased further when measured 28 days after the second dose. CONCLUSIONS: AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2105290

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 1

  1. COVID-19 Vaccine Tracker. Oxford/AstraZeneca: AZD1222. 2021 (https://covid19.trackvaccines.org/vaccines/4/).

Cited by

See all 670

Metadata

Authors
Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., Solis, J., Carr, Q. O., Oyedele, T., Buchbinder, S., Cowden, J., Vargas, S. L., Guerreros Benavides, A., Call, R., Keefer, M. C., Kirkpatrick, B. D., Pullman, J., Tong, T., Brewinski Isaacs, M., Benkeser, D., Janes, H. E., Nason, M. C., Green, J. A., Kelly, E. J., Maaske, J., Mueller, N., Shoemaker, K., Takas, T., Marshall, R. P., Pangalos, M. N., Villafana, T., & Gonzalez-Lopez, A.
Affiliations
  • Columbia University Irving Medical Center (US)
  • From the University of Rochester School of Medicine and Dentistry (A.R.F., M.C.K.) and Rochester Regional Health (A.R.F.), Rochester, and Vagelos College of Physicians and Surgeons, New York Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases (M.E.S.) and the New York University Vaccine Center (M.J.M.), New York — all in New York; Biometrics (I.H.) and Infectious Diseases (J.A.G.), Late-Stage Development, Respiratory and Immunology (R.P.M.), Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, United Kingdom; Biometrics (S.S., K.S.) and Infectious Diseases, Late-Stage Development, Respiratory and Immunology (J.M., T. Takas, T.V., A.G.-L.), Translational Medicine, Microbial Sciences, Biopharmaceuticals Research and Development (E.J.K.), and Clinical Development, Early Global Development, Oncology Research and Development (N.M.), AstraZeneca, Gaithersburg, the Walter Reed Army Institute of Research, Silver Spring (M.L.R.), t...
Corresponding author
Villafana, Tonya
Venue
New England Journal of Medicine
Published
2021-12-16
Volume
385
Issue
25
Pages
2348-2360
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3202234535
Cited by
670
References
21
Citations by year
2026: 33 · 2025: 72 · 2024: 97 · 2023: 185 · 2022: 259 · 2021: 24
FWCI
44.70
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • United States Government (Agreement No. W15QKN-20-9-1003)
  • National Institute of Allergy and Infectious Diseases (UM1 AI 148372, UM1 AI 148450, UM1 AI 148574, UM1 AI 148684, UM1 AI 148684-03, UM1 AI 68614HVTN, UM1 AI 68618, UM1 AI 68619, UM1 AI 68635, UM1 AI 68636)
  • Biomedical Advanced Research and Development Authority (W15QKN-21-9-1003)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords
ChAdOx1 nCoV-19 vaccine, COVID-19 vaccines, SARS-CoV-2, vaccine efficacy, vaccine safety, immunogenicity, neutralizing antibodies, nucleocapsid antibodies, older adults, adverse events
MeSH terms
Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, Vaccine Efficacy, ChAdOx1 nCoV-19, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Chile, Double-Blind Method, Female, Humans, Male, Middle Aged, Peru, United States, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. https://app.cochat.ai/papers/10.1056/nejmoa2105290
The paper
Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., . . . Gonzalez-Lopez, A. (2021). Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2105290

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.